This finding suggests a potential mechanism that may contribute to the higher circulating levels of CD4+ T cells expressing IL-17F (this study) and IL-17A [18] observed in CLL patients. This evidence concerns the gene IL17A and B-cell chronic lymphocytic leukemia.